Insider Selling: SI-BONE, Inc. (NASDAQ:SIBN) CEO Sells 9,967 Shares of Stock

SI-BONE, Inc. (NASDAQ:SIBN) CEO Laura Francis sold 9,967 shares of the stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $13.84, for a total transaction of $137,943.28. Following the completion of the transaction, the chief executive officer now directly owns 492,923 shares in the company, valued at $6,822,054.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

SI-BONE Price Performance

Shares of SIBN stock traded down $0.14 on Tuesday, reaching $14.18. The company had a trading volume of 234,859 shares, compared to its average volume of 400,173. The stock has a market capitalization of $591.16 million, a PE ratio of -13.01 and a beta of 1.20. The company has a quick ratio of 8.12, a current ratio of 9.17 and a debt-to-equity ratio of 0.22. The business’s 50-day moving average is $14.13 and its 200 day moving average is $15.50. SI-BONE, Inc. has a one year low of $11.76 and a one year high of $23.25.

SI-BONE (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.04. SI-BONE had a negative return on equity of 24.27% and a negative net margin of 27.10%. The firm had revenue of $39.97 million for the quarter, compared to analyst estimates of $38.95 million. During the same period last year, the firm posted ($0.30) earnings per share. Equities research analysts forecast that SI-BONE, Inc. will post -0.89 EPS for the current fiscal year.

Hedge Funds Weigh In On SI-BONE

Several large investors have recently modified their holdings of the business. Granahan Investment Management LLC increased its position in SI-BONE by 13.2% during the 4th quarter. Granahan Investment Management LLC now owns 1,286,450 shares of the company’s stock valued at $27,003,000 after purchasing an additional 150,217 shares during the period. Bullseye Asset Management LLC lifted its holdings in SI-BONE by 218.6% in the fourth quarter. Bullseye Asset Management LLC now owns 102,024 shares of the company’s stock valued at $2,141,000 after buying an additional 70,000 shares during the period. Wellington Management Group LLP boosted its position in SI-BONE by 34.9% during the fourth quarter. Wellington Management Group LLP now owns 817,048 shares of the company’s stock valued at $17,150,000 after acquiring an additional 211,209 shares during the last quarter. Bellevue Group AG acquired a new stake in SI-BONE during the 4th quarter worth about $2,628,000. Finally, Champlain Investment Partners LLC lifted its stake in shares of SI-BONE by 104.8% in the 1st quarter. Champlain Investment Partners LLC now owns 2,453,147 shares of the company’s stock valued at $40,158,000 after purchasing an additional 1,255,610 shares during the period. Institutional investors own 98.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Truist Financial lowered their price target on shares of SI-BONE from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. JMP Securities reissued a “market outperform” rating and set a $32.00 price target on shares of SI-BONE in a report on Tuesday, May 7th. Morgan Stanley reduced their price target on SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, Needham & Company LLC lowered their price target on shares of SI-BONE from $27.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, SI-BONE presently has a consensus rating of “Buy” and an average price target of $23.00.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.